Autonomous system
AS1011 ACCUTAR-NA-01
Unclassified ARIN
Summary
Accutar Biotechnology
enterprise legacy
The corporate network of Accutar Biotechnology, an AI-driven drug discovery
company, carried under the handle ACCUTAR-NA-01 (its North American block).
What it's used for
- Enterprise connectivity for a clinical-stage biotech that pairs computational drug design with wet-lab validation.
Notable
- ARIN reassigned AS1011 to Accutar in 2022, so the low number is a recent allocation and carries no early-internet pedigree.
- The registrant of record is the company's Canadian entity, though Accutar itself is US-based, founded in 2015 with offices in Brooklyn, New York.
Interesting
- Accutar's platform has advanced its own candidates into FDA clinical trials, including an oral breast-cancer drug granted Fast Track designation.
This description is AI-generated, best-effort context — not authoritative, and provided without any guarantee of accuracy. Source, and how to suggest an edit.
Address space
Summary
| Country | Name | Prefixes |
|---|---|---|
| CA | Canada | 3 |
Registry
Allocation record
- Registry
- ARIN
- Handle
AS1011- Registry name
- ACCUTAR-NA-01
- Registrant
- Accutar Biotechnology (Canada) Inc.
- Abuse contact
- na-it@accutarbio.com
- Registered
- 2022-06-29
- Last changed
- 2022-06-29
- Status
- active
Reputation
Classification and threat
Unclassified Not in the curated lists. Most of the ~80,000 allocated ASNs are not.
No IC3 indicators Nothing from the FBI IC3 feed.
Threat data is alpha. Absence of an indicator is not evidence of good behaviour, only of absence from this one feed.
Elsewhere